EmaxHealth Health News
Home » Personal Health » Prescription Drugs

Amgen Criticizes Part Of Medicare Decision On Payments For Anemia Treatment

Ads by Google

All About:
  • Prescription Drugs

By Armen Hareyan on August 3, 2007 - 7:03am for eMaxHealth

Amgen on Wednesday criticized part of a final decision announced on Monday by CMSthat will limit Medicare coverage for anemia medications -- Aranesp andEpogen, manufactured by the company, and Procrit, manufactured by Johnson & Johnson -- in cancer patients, Reuters/New York Times reports (Reuters/New York Times,8/2). According to the 61-page "national coverage determination,"Medicare will cover the medications, synthetic forms of the proteinerythropoietin, to treat anemia caused by chemotherapy but not anemiacaused by cancer. In addition, under the decision, Medicare will coverthe anemia medications in cancer patients whose hemoglobin levelsdecrease to less than 10 grams per deciliter of blood. The decisionalso will allow local Medicare contractors to determine whether tocover the anemia medications for use in patients with myelodysplasticsyndrome, a condition that can lead to leukemia (Kaiser Daily Health Policy Report, 7/31).

Amgensaid that the provision under which Medicare will not cover the anemiamedications in cancer patients whose hemoglobin levels are higher than10 grams per deciliter of blood might increase the need fortransfusions and compromise quality of care, as many physicians seek tomaintain hemoglobin levels of 11 to 12 grams per deciliter in patients.

In addition, the provision contradicts recommendations on the use of the medications approved by FDA, as well as a recommendation from the agency's Oncologic Drugs Advisory Committee, and guidelines from the American Society of Clinical Oncology and the American Society of Hematology.

RogerPerlmutter, executive vice president for global research anddevelopment for Amgen, said, "In our view, restricting coverage in thisway is unreasonable, impractical and unworkable" (Reuters/New York Times,8/2). He added, "The coverage restrictions placed on the FDA-approvedindication have no scientific basis and are incompatible with goodclinical practice" (Costello, Los Angeles Times, 8/2).

Reprinted with permission from kaisernetwork \t\t\t\t\t\t\t

Reprinted with permission fromkaisernetwork.org.You can view the entire KaiserDaily Health Policy Report, search the archives, andsign up for email delivery at kaisernetwork.org/email. The Kaiser Daily Health Policy Report is published forkaisernetwork.org,a free service of The Henry J. Kaiser Family Foundation.

Source: 
kaisernetwork.org

eMaxHealth welcomes yourcomments and feedback on this story without registration, but keep the comments meaningful please. Links are not accepted.

  • Add new comment

Similar Stories

  • An Explanation of Xanax, Drug Prescribed for Whitney Houston
  • Vertex Kalydeco for Cystic Fibrosis Approved by FDA Ahead of Schedule
  • Israeli researchers discover method to fight superbugs
  • FDA proposal would accelerate approval of generic drugs
  • Pradaxa vs. Warfarin: Should Cardiac Patients Worry?

 Dr. Oz Promotes Magnet Cure
 Skin Care Secrets in Your Kitchen
 3 Gadgets to Make You Look 10 Years Younger
 Catalase is the Culprit for Gray Hair
 Vibration Therapy Helps Chronic Pain
 What If Antidepressants Don't Work
 When Obesity is OK for Some

Health Categories

 EMAXHEALTH HOME
 AFFORDABLE HEALTH INSURANCE
 DIET & WEIGHT LOSS
 FITNESS & EXERCISE
 MEN'S HEALTH
 WOMEN'S HEALTH
 BEAUTY
 ALTERNATIVE MEDICINE
 CANCER TREATMENT
 AGING
 DISEASE and CONDITION
 MENTAL HEALTH
 GENERAL HEALTH
 PERSONAL HEALTH
 GOURMET FOOD & HEALTH
 HEALING & SPIRITUALITY
 MONEY AND HEALTH
 Comment Moderation
  • Health RSS Feeds
  • Privacy Policy
  • Disclaimer
  • About Us
  • Editorial Review Process
  • Advertise
  • Contact
  • Contributors
Copyright eMaxhealth.com 2005-2012. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.